Related Experiment Video
Updated: Aug 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Gemfibrozil in dyslipidaemia
S C Kundu1, S Roxy, S K Batabyal
1Dept. of Biochemistry, B.R. Singh Hosp., Calcutta.
Abstract:
A new lipid regulating agent, Gemfibrozil was evaluated in different types of dyslipidaemias. Out of a total of 34 patients, all completed 12 weeks' treatment and 26 completed 24 weeks' of treatment. A significant reduction in total cholesterol, LDL-c triglyceride and apo-B and an increase in HDL cholesterol and its apoprotein--apo-A were observed. The patients belonged to hyperlipidaemias--types IIa, IIb, and IV. Patients' compliance was good and side effects were minimal.
Related Concept Videos
Lipid Digestion
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

